A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Eli Lilly and Company
Study ID
NCT05929066
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Retatrutide — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.

Key Dates

Start date
Jul 10, 2023
Status verified
Jun 2026
Primary completion
Apr 6, 2026
Completion
Apr 30, 2026

Study Design

Enrollment
2,335 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Retatrutide Dose 1
    Participants will receive retatrutide subcutaneously (SC).
  • Experimental: Retatrutide Dose 2
    Participants will receive retatrutide SC.
  • Experimental: Retatrutide Dose 3
    Participants will receive retatrutide SC.
  • Placebo Comparator: Placebo
    Participants will receive placebo.
  • Experimental: Retatrutide Extension Period
    Participants will receive retatrutide after the placebo-controlled 80 week treatment period for an additional 24 weeks.

Primary Outcome Measure

Percent Change From Baseline in Body Weight [ Time Frame: Baseline, Week 80 ]

Locations (39)

FacilityCityStateZIP
Arizona Research CenterPhoenixArizona85053
Central Phoenix Medical ClinicPhoenixArizona85020
Medical InvestigationsLittle RockArkansas72211
Neuro-Pain Medical CenterFresnoCalifornia93710
Valley ResearchFresnoCalifornia93720
Artemis Institute for Clinical ResearchSan DiegoCalifornia92103
University of Colorado Anschutz Medical CampusAuroraColorado80045
Yale University School of MedicineNew HavenConnecticut06519
Chase Medical Research, LLCWaterburyConnecticut06708
Teradan Clinical Trials, LLCBrandonFlorida33511
New Horizon Research CenterMiamiFlorida33165
Suncoast Research GroupMiamiFlorida33135
Clinical Neuroscience SolutionsOrlandoFlorida32801
Progressive Medical ResearchPort OrangeFlorida32127
NeuroTrials Research IncAtlantaGeorgia30328
North Georgia Clinical ResearchWoodstockGeorgia30189
East-West Medical Research InstituteHonoluluHawaii96814
Northwestern UniversityChicagoIllinois60611
Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research CooperativeSpringfieldIllinois62711
Brengle Family MedicineIndianapolisIndiana46260
Cotton O'Neil Diabetes & EndocrinologyTopekaKansas66606
MedVadis Research CorporationWalthamMassachusetts02451
Great Lakes Research Group, Inc.Bay CityMichigan48706
StudyMetrix ResearchCity of Saint PetersMissouri63303
Clinvest Research LLCSpringfieldMissouri65807
Palm Research Center TenayaLas VegasNevada89128
Rochester Clinical Research, LLCRochesterNew York14609
Carteret Medical GroupMorehead CityNorth Carolina28557
Trial Management Associates - Wilmington - Floral ParkwayWilmingtonNorth Carolina28403
Lillestol ResearchFargoNorth Dakota58104
Altoona Center For Clinical ResearchDuncansvillePennsylvania16635
Tribe Clinical Research, LLCGreenvilleSouth Carolina29607
Tribe Clinical Research - SpartanburgSpartanburgSouth Carolina29301
Vanderbilt Health One Hundred OaksNashvilleTennessee37204
FutureSearch Trials of NeurologyAustinTexas78731
Juno ResearchHoustonTexas77040
Advanced Research InstituteOgdenUtah84405
Northwest Clinical Research CenterBellevueWashington98007
Rainier Clinical Research CenterRentonWashington98057

Related coverage on Hipa.ai

Find similar trials in Phoenix, AZ

Related Studies